Format

Send to

Choose Destination
J Am Acad Dermatol. 2004 Aug;51(2):200-4.

Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.

Author information

1
Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

BACKGROUND:

Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL).

OBJECTIVE:

To assess the toxicity, safety, and efficacy of etanercept (soluble TNF receptor) in patients with relapsed CTCL.

METHODS:

Etanercept was administered twice weekly at a dose of 25 mg subcutaneously. Patients with improvement after two months could be continued on treatment.

RESULTS:

Twelve out of the 13 patients enrolled on study were evaluable (Stage I-IIA, 3 patients; Stage IIB-IV disease, 9 patients). The median number of previous therapies was 7 (range, 3-12). Etanercept induced partial remission in one patient (8%) and minor response in one patient (8%), both of whom had Stage IB disease. Most patients experienced no side effects.

CONCLUSION:

This pilot study suggests that etanercept is safe and generally well tolerated in patients with CTCL. The effect of etanercept in a larger cohort of patients with early disease merits investigation.

PMID:
15280837
DOI:
10.1016/j.jaad.2003.05.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center